Qian and colleagues [137] took advantage of the presence of Glypican-1 (GPC1) in extracellular vesicles (EVs) to determine if the change in GPC1+ cells in EVs could be a predictor of the consequences of RIAC for advanced pancreatic cancer patients. This evidence concerns the gene GPC1 and pancreatic neoplasm.